Horizon Therapeutics Plc - Company Profile
Powered by
All the data and insights you need on Horizon Therapeutics Plc in one report.
- Save hours of research time and resources with
our up-to-date Horizon Therapeutics Plc Strategy Report
- Understand Horizon Therapeutics Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Horizon Therapeutics Plc Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Horizon Therapeutics Plc Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 18 Aug 2022 | Lorem |
LoA Update: Horizon’s Raviciti has bleak advancement prospects in cystic fibrosis following Phase I/II trial termination | 28 Mar 2022 | William Newton |
Horizon’s Phase III extension trial for teprotumumab accrues 35 patients from pivotal trial in thyroid eye disease, exec says | 21 Oct 2019 | Shuan Sim |
Roche/Chugai’s satralizumab and Viela Bio’s inebilizumab unlikely to receive label inclusion for AQP4- patients in neuromyelitis optica spectrum disorder, experts say | 26 Sep 2019 | Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer